The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Therapeutic antibodies for autoimmunity and inflammation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,593
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. H., Riordan, G. S., & Whitlow, M. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,502
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Self-citationTumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
IL‐1, IL‐18, and IL‐33 families of cytokines
Arend, W. P., Palmer, G., & Gabay, C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00624.x · Cited by 912
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“A second widely applicable and comparably successful method for increasing the IgG ADCC activity is through tailoring of Fc glycosylatio”
MethodMacGlashan, D. W., Bochner, B. S., Adelman, D. C., Jardieu, P. M., Togias, A., McKenzie-White, J., Sterbinsky, S. A., Hamilton, R. G., & Lichtenstein, L. M. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.3.1438 · Cited by 823
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 1×
“Eculizumab lacks the ability to bind FcγRs and activate complement, which are common attributes for human IgG2 and IgG4, respectivel”
BackgroundUmaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Spectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
Kelley, B. (2009) · mAbs · doi:10.4161/mabs.1.5.9448 · Cited by 667
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Designing CD4 immunoadhesins for AIDS therapy
Capon, D. J., Chamow, S. M., Mordenti, J., Marsters, S. A., Gregory, T., Mitsuya, H., Byrn, R. A., Lucas, C., Wurm, F. M., Groopman, J. E., et al. (1989) · Nature · doi:10.1038/337525a0 · Cited by 615
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A. C., Tak, P. P., & Wolbink, G. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065615 · Cited by 562
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
Self-citationMetabolic properties of IgG subclasses in man
Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 526
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 517
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Self-citationEnhancement of therapeutic protein in vivo activities through glycoengineering
Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., Grant, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt799 · Cited by 510
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
(2008) · Arthritis & Rheumatism · doi:10.1002/art.23363 · Cited by 505
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Schellenberger, V., Wang, C.-W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1588 · Cited by 462
Omalizumab-induced reductions in mast cell FcεRI expression and function
Beck, L. A., Marcotte, G. V., MacGlashan, D., Togias, A., & Saini, S. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.06.032 · Cited by 456
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Self-citationOptimization of humanized IgGs in glycoengineered Pichia pastoris
Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N., Bobrowicz, P., Choi, B.-K., Cook, W. J., Cukan, M., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M., & Cioppa, G. D. (2005) · Allergy · doi:10.1111/j.1398-9995.2004.00770.x · Cited by 401
Joosten, L. A. B., Helsen, M. M. A., van de Loo, F. A. J., & van den Berg, W. B. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390513 · Cited by 400
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24638 · Cited by 398
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Bostrom, J., Yu, S.-F., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K., Man, W., Peale, F., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 370
Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences
Acqua, W. F. D., Woods, R. M., Ward, E. S., Palaszynski, S. R., Patel, N. K., Brewah, Y. A., Wu, H., Kiener, P. A., & Langermann, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5171 · Cited by 368
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Omalizumab treatment downregulates dendritic cell FcεRI expression
Prussin, C., Griffith, D. T., Boesel, K. M., Lin, H., Foster, B., & Casale, T. B. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.003 · Cited by 349
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
Bisikirska, B., Colgan, J., Luban, J., Bluestone, J. A., & Herold, K. C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23961 · Cited by 339
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Petkova, S. B., Akilesh, S., Sproule, T. J., Christianson, G. J., Al Khabbaz, H., Brown, A. C., Presta, L. G., Meng, Y. G., & Roopenian, D. C. (2006) · International Immunology · doi:10.1093/intimm/dxl110 · Cited by 314
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Development trends for therapeutic antibody fragments
Nelson, A. L., & Reichert, J. M. (2009) · Nature Biotechnology · doi:10.1038/nbt0409-331 · Cited by 305
Weinblatt, M., Schiff, M., Goldman, A., Kremer, J., Luggen, M., Li, T., Chen, D., & Becker, J.-C. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055111 · Cited by 300
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Engineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates
Hinton, P. R., Johlfs, M. G., Xiong, J. M., Hanestad, K., Ong, K. C., Bullock, C., Keller, S., Tang, M. T., Tso, J. Y., Vásquez, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300470200 · Cited by 273
Development and function of TH17 cells in health and disease
Louten, J., Boniface, K., & de Waal Malefyt, R. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.04.003 · Cited by 266
Monoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment
VAN DEN BERG, W. B., JOOSTEN, L. A. B., HELSEN, M., & VAN DE LOO, F. A. J. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06517.x · Cited by 251
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
van Meerten, T., van Rijn, R. S., Hol, S., Hagenbeek, A., & Ebeling, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0066 · Cited by 250
Increasing the serum persistence of an IgG fragment by random mutagenesis
Ghetie, V., Popov, S., Borvak, J., Radu, C., Matesoi, D., Medesan, C., Ober, R. J., & Ward, E. S. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-637 · Cited by 241
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Vultaggio, A., Matucci, A., Nencini, F., Pratesi, S., Parronchi, P., Rossi, O., Romagnani, S., & Maggi, E. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02280.x · Cited by 238
Design and production of novel tetravalent bispecific antibodies
Coloma, M. J., & Morrison, S. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-159 · Cited by 236
Almagro, J. C., & Fransson, J. (2008) · PubMed · doi:10.2741/2786 · Cited by 220
Minard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C. M., Hamaguchi, Y., Haas, K. M., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-01-135160 · Cited by 218
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Bolt, S., Routledge, E., Lloyd, I., Chatenoud, L., Pope, H., Gorman, S. D., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230216 · Cited by 218
Choy, E. H. S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.10.1133 · Cited by 213
Genovese, M. C., Kaine, J. L., Lowenstein, M. B., Giudice, J. D., Baldassare, A., Schechtman, J., Fudman, E., Kohen, M., Gujrathi, S., Trapp, R. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23732 · Cited by 207
Kenanova, V., Olafsen, T., Crow, D. M., Sundaresan, G., Subbarayan, M., Carter, N. H., Ikle, D. N., Yazaki, P. J., Chatziioannou, A. F., Gambhir, S. S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.622.65.2 · Cited by 206
Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206
Structural characterization of a human Fc fragment engineered for lack of effector functions
Oganesyan, V., Gao, C., Shirinian, L., Wu, H., & Dall'Acqua, W. F. (2008) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444908007877 · Cited by 197
Fully human antibodies from transgenic mouse and phage display platforms
Lonberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 188
Woodle, E. S., Xu, D., Zivin, R. A., Auger, J., Charette, J., O'Laughlin, R., Peace, D., Jolliffe, L. K., Haverty, T., Bluestone, J. A., et al. (1999) · Transplantation · doi:10.1097/00007890-199909150-00003 · Cited by 188
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Single-domain antibodies as building blocks for novel therapeutics
SAERENS, D., GHASSABEH, G., & MUYLDERMANS, S. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.006 · Cited by 186
Beers, S. A., Chan, C. H. T., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., & Glennie, M. J. (2008) · Blood · doi:10.1182/blood-2008-04-149161 · Cited by 180
Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500815200 · Cited by 180
Kavanaugh, A., Rosengren, S., Lee, S. J., Hammaker, D., Firestein, G. S., Kalunian, K., Wei, N., & Boyle, D. L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.074229 · Cited by 178
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)
Herold, K. C., Burton, J. B., Francois, F., Poumian-Ruiz, E., Glandt, M., & Bluestone, J. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16090 · Cited by 177
Ivanov, A., Beers, S. A., Walshe, C. A., Honeychurch, J., Alduaij, W., Cox, K. L., Potter, K. N., Murray, S., Chan, C. H. T., Klymenko, T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37884 · Cited by 177
Alegre, M.-L., Peterson, L. J., Xu, D., Sattar, H. A., Jeyarajah, D. R., Kowalkowski, K., Thistlethwaite, J. R., Zivin, R. A., Jolliffe, L., & Bluestone, J. A. (1994) · Transplantation · doi:10.1097/00007890-199457110-00001 · Cited by 171
Datta-Mannan, A., Witcher, D. R., Tang, Y., Watkins, J., & Wroblewski, V. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607161200 · Cited by 170
Engineered therapeutic antibodies with improved effector functions
Kubota, T., Niwa, R., Satoh, M., Akinaga, S., Shitara, K., & Hanai, N. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01222.x · Cited by 168
Ferrer, M., Kinét, J.-P., & Kaplan, A. P. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70176-9 · Cited by 164
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Johnson, N. A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L. H., Chhanabhai, M., Brinkman, R. R., Connors, J. M., Weng, A. P., et al. (2009) · Blood · doi:10.1182/blood-2008-09-177469 · Cited by 163
Ten Years of Orthoclone OKT3 (Muromonab-CD3): A Review
Smith, S. L. (1996) · Journal of Transplant Coordination · doi:10.1177/090591999600600304 · Cited by 163
Eckman, J. A., Hamilton, R. G., Gober, L. M., Sterba, P. M., & Saini, S. S. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.55 · Cited by 161
[17] Bispecific monoclonal antibodies from hybrid hybridomas
Suresh, M. R., Cuello, A. C., & Milstein, C. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)21019-8 · Cited by 160
Jung, S. T., Reddy, S. T., Kang, T. H., Borrok, M. J., Sandlie, I., Tucker, P. W., & Georgiou, G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908590107 · Cited by 160
Recombinant bispecific antibodies for cancer therapy
Kontermann, R. E. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00008.x · Cited by 158
Olejniczak, S. H., Stewart, C. C., Donohue, K. A., & Czuczman, M. S. (2006) · Immunological Investigations · doi:10.1080/08820130500496878 · Cited by 145
Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region
Dall’Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., & Wu, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1129 · Cited by 138
Jacobi, A. M., Goldenberg, D. M., Hiepe, F., Radbruch, A., Burmester, G. R., & Dörner, T. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.075762 · Cited by 127
Lu, D., Zhang, H., Ludwig, D. L., Persaud, A., Jimenez, X., Burtrum, D. B., Balderes, P. J., Liu, M., Böhlen, P., Witte, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310132200 · Cited by 124
Yeh, P., Landais, D., Lemaitre, M. M., Maury, I., Crenne, J.-Y., Becquart, J., Murry‐Brelier, A., Boucher, F., Montay, G., & Fleer, R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1904 · Cited by 118
Vaccaro, C., Bawdon, R. E., Wanjie, S., Ober, R. J., & Ward, E. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606304103 · Cited by 117
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Scolnik, P. A. (2009) · mAbs · doi:10.4161/mabs.1.2.7736 · Cited by 102
Wu, C., Hua, Y., Bose, S., Miller, R., Medina, L., Santora, L. C., & Ghayur, T. (2009) · mAbs · doi:10.4161/mabs.1.4.8755 · Cited by 94
When binding is enough: nonactivating antibody formats
Labrijn, A. F., Aalberse, R. C., & Schuurman, J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.05.010 · Cited by 90
Structural characterization of a human Fc fragment engineered for extended serum half-life
Oganesyan, V., Damschroder, M. M., Woods, R. M., Cook, K. E., Wu, H., & Dall’Acqua, W. F. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.01.026 · Cited by 89
Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
Petereit, H.-F., & Rubbert‐Roth, A. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458508098268 · Cited by 87
Recombinant approaches to IgG-like bispecific antibodies
Marvin, J. S., & Zhu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00119.x · Cited by 87
Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis
Vugmeyster, Y., Beyer, J. C., Howell, K., Combs, D., Fielder, P. J., Yang, J., Qureshi, F., Sandlund, B., Kawaguchi, L., Dummer, W., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155050.03916.04 · Cited by 79
Retargeting serum immunoglobulin with bispecific diabodies
Holliger, P., Wing, M. G., Pound, J. D., Bohlen, H., & Winter, G. P. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-632 · Cited by 79
Engineering of stable bispecific antibodies targeting IL-17A and IL-23
Mabry, R., Lewis, K. E., Moore, M. D., McKernan, P. A., Bukowski, T. R., Bontadelli, K., Brender, T., Okada, S. L., Lum, K. D., West, J. W., et al. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp073 · Cited by 64
Human antibody libraries: A race to engineer and explore a larger diversity
Mondon, P., Dubreuil, O., Bouayadi, K., & Kharrat, H. (2007) · Frontiers in bioscience · doi:10.2741/2749 · Cited by 63
Guttman‐Yassky, E., Vugmeyster, Y., Lowes, M. A., Chamian, F. N., Kikuchi, T., Kagen, M. H., Gilleaudeau, P., Lee, E., Hunte, B., Howell, K., et al. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.4 · Cited by 59
Jendreyko, N., Popkov, M., Beerli, R. R., Chung, J., McGavern, D. B., Rader, C. M., & Barbas, C. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307002200 · Cited by 57
Genovese, T., Paola, R. D., Catalano, P., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000127775.70867.0c · Cited by 56
Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies.
Norman, D. J., Chatenoud, L., Cohen, D., Goldman, M., & Shield, C. F. (1993) · PubMed · Cited by 50
Lu, D., Jimenez, X., Zhang, H., Wu, Y. L., Böhlen, P., Witte, L., & Zhu, Z. (2001) · PubMed · Cited by 49
Natsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 45
Wiczling, P., Rosenzweig, M., Vaickus, L., & Jusko, W. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009349376 · Cited by 37
Fossati, G., & Nesbitt, A. M. (2005) · The American Journal of Gastroenterology · doi:10.14309/00000434-200509001-00806 · Cited by 33
Antibody engineering to develop new antirheumatic therapies
Isaacs, J. D. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2594 · Cited by 32
Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation
Chatenoud, L. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.012 · Cited by 26
An integrated science-based approach to drug development
Parren, P. W. H. I., & van de Winkel, J. G. J. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.006 · Cited by 21
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Strategies and challenges for the next generation of therapeutic antibodies
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010) · Nature Reviews Immunology · doi:10.1038/nri2747 · Cited by 847
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Self-citation
Metadata
- Authors
- Chan, A. C., & Carter, P. J.
- Venue
- Nature Reviews Immunology
- Published
- 2010-05
- Volume
- 10
- Issue
- 5
- Pages
- 301-316
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W1971242419
- Cited by
- 837
- References
- 153
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.